REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$14.96 USD
+0.04 (0.27%)
Updated May 28, 2024 04:00 PM ET
After-Market: $14.97 +0.01 (0.07%) 6:14 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
RGNX 14.96 +0.04(0.27%)
Will RGNX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RGNX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RGNX
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
RGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
Other News for RGNX
PTC Therapeutics rallies 18% on EU authorization update for Translarna
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), PepGen Inc. (PEPG) and RegenXBio (RGNX)
Regenxbio price target raised by $2 at H.C. Wainwright, here's why
Evaluating Regenxbio: Insights From 9 Financial Analysts
Cantor picks 14 undervalued biotech stocks worth a second look